<DOC>
	<DOCNO>NCT01095471</DOCNO>
	<brief_summary>This follow-on , multi-centre , open-label , clinical trial . The purpose trial investigate concentration serotype-specific antibody IgG include PCV13 child receive either PCV7 PCV13 primary immunisation 2 , 4 12 month age . We intend recruit interested participant complete Wyeth-sponsored PCV13 infant trial study ( 6096A1-007 ) select study site ( i.e . recruit majority child original study ) . The study start March 2010 , time eldest participant 6096A1-007 study approximately 42 month age . There two visit per participant , 1 month apart . At visit one , participant blood test receive dose PCV13 . At visit 2 , participant blood test offer remain pre-school booster vaccination unless already receive .</brief_summary>
	<brief_title>13 Valent Pneumococcal Conjugate Vaccine - Follow-on Study</brief_title>
	<detailed_description />
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>1 . Participant complete Wyethsponsored PCV13 infant trial study ( 6096A1007 ) one study sit participate followon study . 2 . Aged 3946 month ( inclusive ) time enrolment . 3 . Available entire study period whose parent/legal guardian reach telephone . 4 . Healthy child determine medical history , physical examination , do study nurse ( and/or study doctor require , depend medical history participant physical assessment ) , judgment investigator . 5 . Parent/legal guardian must able complete relevant study procedure study participation . 1 . Has receive dose pneumococcal vaccination license investigational pneumococcal vaccine give part Wyethsponsored PCV13 infant trial study ( 6096A1007 ) . 2 . A previous anaphylactic reaction vaccine vaccinerelated component . 3 . Contraindication vaccination pneumococcal conjugate vaccine . 4 . Bleeding diathesis condition associate prolonged bleeding time would contraindicate intramuscular injection . 5 . Known suspected immune deficiency suppression . 6 . History cultureproven invasive disease cause S pneumoniae . 7 . Major know congenital malformation serious chronic disorder . 8 . Significant neurologic disorder history seizures include febrile seizure , significant stable evolve disorder cerebral palsy , encephalopathy , hydrocephalus , significant disorder . 9 . Receipt blood product gammaglobulin ( include hepatitis B immunoglobulin monoclonal antibody ; eg , synagisB ) . 10 . Participation another investigational study Wyethsponsored PCV13 infant trial study ( 6096A1007 ) . Participation purely observational study acceptable . 11 . Child direct descendant ( child , grandchild ) study site personnel .</criteria>
	<gender>All</gender>
	<minimum_age>39 Months</minimum_age>
	<maximum_age>46 Months</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>7 valent Pneumococcal conjugate vaccine</keyword>
	<keyword>13 valent Pneumococcal conjugate vaccine</keyword>
	<keyword>PCV13</keyword>
	<keyword>PCV7</keyword>
</DOC>